L&C BIO (290650) Q2 2025 earnings summary

Executive summary

• Specializes in bioengineering, manufacturing human tissue grafts, medical devices, cosmeceuticals, and pharmaceuticals, with a focus on R&D and global expansion.

• Major revenue from human tissue grafts and related medical devices, with expanding indications and export markets.

• Recent strategic moves include full acquisition of L&C Bioscience Technology (Kunshan) Co., Ltd and divestment of non-core assets.

Financial highlights

• Consolidated H1 2025 revenue: KRW 38.3 billion, down from KRW 72.1 billion in FY2024.

• Operating loss of KRW 435 million in H1 2025, compared to operating profit of KRW 2.5 billion in FY2024.

• Net loss attributable to owners: KRW 14.2 billion in H1 2025, versus net profit of KRW 141.1 billion in FY2024.

• Cash and cash equivalents increased to KRW 50.6 billion as of June 2025.

Outlook and guidance

• Focus on expanding global market share for tissue-based medical devices and cosmeceuticals.

• Continued investment in R&D for next-generation products and platform technologies.

• Regulatory and market trends support growth in regenerative medicine and cosmeceutical sectors.